loading
前日終値:
$48.43
開ける:
$48.84
24時間の取引高:
11.57M
Relative Volume:
0.91
時価総額:
$97.54B
収益:
$47.70B
当期純損益:
$5.07B
株価収益率:
19.32
EPS:
2.48
ネットキャッシュフロー:
$14.58B
1週間 パフォーマンス:
-1.07%
1か月 パフォーマンス:
-0.21%
6か月 パフォーマンス:
-14.17%
1年 パフォーマンス:
+0.63%
1日の値動き範囲:
Value
$47.72
$49.11
1週間の範囲:
Value
$47.72
$49.58
52週間の値動き範囲:
Value
$42.96
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
名前
Bristol Myers Squibb Co
Name
セクター
Healthcare (1157)
Name
電話
(609) 252-4621
Name
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
職員
34,100
Name
Twitter
@BMSNEWS
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
BMY's Discussions on Twitter

BMY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
47.92 98.09B 47.70B 5.07B 14.58B 2.48
Drug Manufacturers - General icon
LLY
Lilly Eli Co
711.68 625.77B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
179.29 424.47B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
210.60 364.92B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
126.98 240.07B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.37 210.36B 63.43B 16.42B 14.72B 6.49

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-08-05 ダウングレード Daiwa Securities Outperform → Neutral
2025-04-22 開始されました Cantor Fitzgerald Neutral
2025-04-22 開始されました Piper Sandler Overweight
2024-12-16 アップグレード Jefferies Hold → Buy
2024-12-10 再開されました BofA Securities Neutral
2024-11-15 開始されました Wolfe Research Peer Perform
2024-11-13 アップグレード Daiwa Securities Neutral → Outperform
2024-11-12 アップグレード Leerink Partners Market Perform → Outperform
2024-10-25 ダウングレード Citigroup Buy → Neutral
2024-10-17 開始されました Bernstein Mkt Perform
2024-07-29 ダウングレード Barclays Overweight → Equal Weight
2024-03-11 ダウングレード Societe Generale Buy → Hold
2024-02-06 ダウングレード Redburn Atlantic Buy → Neutral
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-11-15 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-11-09 開始されました Deutsche Bank Hold
2023-11-02 ダウングレード Daiwa Securities Outperform → Neutral
2023-10-27 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-10-27 アップグレード HSBC Securities Reduce → Hold
2023-10-27 ダウングレード William Blair Outperform → Mkt Perform
2023-10-20 再開されました UBS Neutral
2023-07-14 開始されました HSBC Securities Reduce
2023-07-10 開始されました SVB Securities Market Perform
2023-06-28 開始されました Daiwa Securities Outperform
2023-03-06 開始されました Jefferies Hold
2023-01-17 開始されました Cantor Fitzgerald Overweight
2022-11-18 開始されました Credit Suisse Neutral
2022-10-10 ダウングレード Guggenheim Buy → Neutral
2022-09-14 ダウングレード Berenberg Buy → Hold
2022-06-03 ダウングレード Raymond James Outperform → Mkt Perform
2022-04-06 再開されました Morgan Stanley Underweight
2021-12-17 開始されました Goldman Buy
2021-12-09 再開されました Wells Fargo Equal Weight
2021-11-19 開始されました BMO Capital Markets Outperform
2021-11-01 ダウングレード Argus Buy → Hold
2021-07-27 再開されました Truist Buy
2021-04-30 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-04-13 アップグレード Truist Hold → Buy
2020-11-16 アップグレード Societe Generale Hold → Buy
2020-11-10 再開されました Bernstein Mkt Perform
2020-11-06 ダウングレード Gabelli & Co Buy → Hold
2020-10-19 アップグレード Guggenheim Neutral → Buy
2020-09-29 開始されました Berenberg Buy
2020-07-28 開始されました Raymond James Outperform
2020-04-02 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-23 ダウングレード Societe Generale Buy → Hold
2020-02-27 開始されました Barclays Equal Weight
2020-01-06 再開されました Citigroup Buy
2019-12-13 アップグレード Argus Hold → Buy
2019-11-22 再開されました Morgan Stanley Equal-Weight
2019-10-17 再開されました BofA/Merrill Buy
2019-08-14 アップグレード Atlantic Equities Neutral → Overweight
2019-05-28 開始されました Goldman Buy
2019-05-20 ダウングレード Argus Buy → Hold
2019-05-03 アップグレード Barclays Equal Weight → Overweight
2019-05-03 再開されました JP Morgan Overweight
2019-01-15 アップグレード Societe Generale Sell → Buy
2018-10-22 ダウングレード Citigroup Buy → Neutral
すべてを表示

Bristol Myers Squibb Co (BMY) 最新ニュース

pulisher
Aug 20, 2025

Agilent, Bristol Myers win FDA nod for cancer test (A:NYSE) - Seeking Alpha

Aug 20, 2025
pulisher
Aug 20, 2025

Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.

Aug 20, 2025
pulisher
Aug 19, 2025

Bristol Myers Squibb Stock Surges on FDA Breakthrough Designation for Lung Cancer Drug Despite Ranking 217th in Trading Volume - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

Aug 19, 2025
pulisher
Aug 19, 2025

Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan... - Medical Dialogues

Aug 19, 2025
pulisher
Aug 19, 2025

Bristol Myers Squibb's Lung Cancer Drug Secures FDA Breakthrough Status - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Bristol Myers Squibb Company stock outlook for YEAR2025 Volume Leaders & AI Driven Stock Movement Reports - Newser

Aug 19, 2025
pulisher
Aug 18, 2025

Israel issues first antitrust fine to a global pharmaceutical company - Global Competition Review

Aug 18, 2025
pulisher
Aug 18, 2025

FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb - Enidnews.com

Aug 18, 2025
pulisher
Aug 18, 2025

Bristol Myers and SystImmune’s lung cancer drug gets FDA boost - Investing.com

Aug 18, 2025
pulisher
Aug 18, 2025

The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific - Yahoo Finance

Aug 18, 2025
pulisher
Aug 18, 2025

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times

Aug 18, 2025
pulisher
Aug 17, 2025

Bristol Myers (BMY) Partners with Bain Capital to Create Immunology Therapies - uk.finance.yahoo.com

Aug 17, 2025
pulisher
Aug 16, 2025

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Benzinga

Aug 16, 2025
pulisher
Aug 15, 2025

Lowe's, Bristol-Myers, and Marvell Technology: Key Research Reports - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology - Yahoo Finance

Aug 15, 2025
pulisher
Aug 15, 2025

Bristol-Myers Squibb’s Promising Phase 3 Alzheimer’s Study: Market Implications - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Bristol-Myers Squibb’s New Study on NSCLC Treatment: Market Implications - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace

Aug 15, 2025
pulisher
Aug 14, 2025

Bristol-Myers Squibb’s Promising Phase 3 Study on Deucravacitinib for Sjögren’s Syndrome - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Bristol-Myers Squibb and Incyte’s Cancer Study Update: Market Implications - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Bristol-Myers Squibb’s New Psoriasis Study: A Long-Term Safety Evaluation - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Anal Cancer Market Is Going to Boom | Major Giants Merck & Co., Roche, Bristol-Myers Squibb, Pfizer - newstrail.com

Aug 14, 2025
pulisher
Aug 13, 2025

Bristol-Myers Squibb stock price target lowered to $45 at Cantor Fitzgerald - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 12, 2025

Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Competitive Analysis of Bristol Myers Squibb, Pfizer, Eli Lilly, Merck, Novartis, Amgen, F. Hoffmann-La RocheResearchAndMarkets.com - Bluefield Daily Telegraph

Aug 12, 2025
pulisher
Aug 12, 2025

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - uk.finance.yahoo.com

Aug 12, 2025
pulisher
Aug 12, 2025

Can Bristol Myers Squibb Company lead its sector in growthHigh Yield Growth Opportunities - mustnews.co.kr

Aug 12, 2025
pulisher
Aug 11, 2025

Hung Trinh: BioNTech SE and Bristol Myers Squibb Partner on Next-Gen Bispecific Antibody for Solid Tumors - Oncodaily

Aug 11, 2025
pulisher
Aug 11, 2025

Bristol-Myers Squibb’s MYK-224 Study Termination: What Investors Need to Know - MSN

Aug 11, 2025
pulisher
Aug 10, 2025

Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - Oncodaily

Aug 10, 2025
pulisher
Aug 09, 2025

Jim Cramer on Bristol-Myers: “Have Not Been Recommending the Stock” - Insider Monkey

Aug 09, 2025
pulisher
Aug 08, 2025

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Bristol Myers Squibb Named Top Dividend Stock With Insider Buying and 5.47% Yield (BMY) - Nasdaq

Aug 08, 2025
pulisher
Aug 08, 2025

Bristol-Myers Squibb’s Promising Phase 3 Study on BMS-986278: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Bristol Myers Squibb (NYSE:BMY) Cut to Neutral at Daiwa Capital Markets - Defense World

Aug 08, 2025
pulisher
Aug 07, 2025

Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast Period (2024-2032), DelveInsight Analyzes by DelveInsight | Johnson & Johnson, Gadeta, Bristol-Myers Squibb, Bluebird - Barchart.com

Aug 07, 2025
pulisher
Aug 06, 2025

Stock Analysis | Bristol-Myers Squibb OutlookNavigating Weak Technicals Amid Mixed Fundamentals - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL - BioPharm International

Aug 06, 2025
pulisher
Aug 06, 2025

Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised - Investing.com Nigeria

Aug 06, 2025
pulisher
Aug 06, 2025

Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised By Investing.com - Investing.com South Africa

Aug 06, 2025
pulisher
Aug 05, 2025

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

3 Dividend Stocks for August 2025 - Morningstar

Aug 05, 2025
pulisher
Aug 05, 2025

Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - MSN

Aug 05, 2025
pulisher
Aug 04, 2025

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity (NYSE:BMY) - Seeking Alpha

Aug 04, 2025
pulisher
Aug 04, 2025

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327 - insights.citeline.com

Aug 04, 2025
pulisher
Aug 04, 2025

Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb Company (BMY) - Insider Monkey

Aug 04, 2025
pulisher
Aug 04, 2025

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - Yahoo Finance

Aug 04, 2025
pulisher
Aug 04, 2025

BioNTech shares rise over 2% as Q2 revenue doubles, Bristol Myers deal bolsters outlook - Investing.com

Aug 04, 2025
pulisher
Aug 04, 2025

Bristol-Myers Squibb: Is the 30% Pullback a Strategic Buy Opportunity? - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 22.84% Upside Potential with a Robust Dividend Yield - DirectorsTalk Interviews

Aug 04, 2025

Bristol Myers Squibb Co (BMY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$51.35
price up icon 1.46%
$114.77
price down icon 1.18%
drug_manufacturers_general PFE
$25.88
price up icon 0.54%
$293.72
price down icon 0.69%
drug_manufacturers_general NVO
$56.98
price up icon 2.76%
drug_manufacturers_general MRK
$87.37
price up icon 1.50%
大文字化:     |  ボリューム (24 時間):